TNBC Clinical Trials in Los Angeles, California
10 recruitingLos Angeles, California
Showing 1–10 of 10 trials
Recruiting
Phase 1
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Breast CancerTNBC - Triple-Negative Breast Cancer
Stephen Shiao35 enrolled1 locationNCT05491226
Recruiting
Phase 1
Study of XB010 in Subjects With Solid Tumors
Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 2
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
TNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast CarcinomaTNBC
Cedars-Sinai Medical Center34 enrolled4 locationsNCT07017673
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
Gastric CancerNon-small Cell Lung Cancer (NSCLC)Cervical Cancer+11 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 2
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Breast CancerHER2-negative Breast CancerTNBC - Triple-Negative Breast Cancer
Processa Pharmaceuticals90 enrolled13 locationsNCT06568692